SARS-CoV-2 Neutralising Antibody Tests

Measuring neutralising antibodies to Wild Type (Wuhan), Delta & Omicron variants following vaccination or natural infection

Accurate indicator of protective immunity against SARS-CoV-2 variants

  • null
    Determine if an effective antibody response has been generated to circulating SARS-CoV-2 variants following vaccination or natural infection
  • null
    Identify individuals with a sub-optimal vaccine response to inform eligibility for booster vaccination
  • null
    Provide accurate estimates of herd immunity at a local and national population level

The Randox CE marked SARS-CoV-2 Wild Type Surrogate Virus Neutralisation Assay (EV4454) and Delta SARS-CoV-2 Surrogate Virus Neutralisation Assay (EV4477) detect antibodies that block interaction of the spike protein receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2). Randox Laboratories currently have in development an assay designed to detect antibodies against SARS-CoV-2 Omicron variant (EV4490).

Rapid, high throughput tests that measure neutralising antibodies against circulating SARS-CoV-2 variants are of significant interest to Clinical, Pharmaceutical, Government and Research organisations. Vaccine breakdown is of growing concern globally with the emergence of SARS-CoV-2 variants such as the now dominant Delta & Omicron strains. Randox have available innovative testing solutions to accurately measure protection against infection and to identify individuals where booster vaccination is required. This can help reduce infection rates and onward virus transmission by ensuring sufficient levels of herd immunity.



Ordering Information

AssayCat Code
Wild Type SARS-CoV-2 Surrogate Virus Neutralisation AssayEV4454
Delta SARS-CoV-2 Surrogate Virus Neutralisation AssayEV4477
Omicron SARS-CoV-2 Surrogate Virus Neutralisation AssayEV4490
Evidence Investigator AnalyserEV3602

Available Platform

Evidence Investigator

Specificty of 100% and sensitivity of 98% compared ro coventional virus neutralisation tests

Semi-automated solution suitable for medium to high throughput testing

Direct sample addition to biochip well.  No off-board sample incubation required

Results available in 1.5 hours without the need for biosafety level 3 cabinet

Limited sample volume requirements

Comprehensive immunoassay and molecular test menu available

Evidence Investigator

Randox Clinical Laboratory Service (RCLS)

RCLS specialise in offering an esoteric biomarker testing service, utilising the experience and knowledge Randox has built over 40 years of producing high quality in vitro diagnostics.

RCLS strive to provide a clinical laboratory testing service to meet the time sensitive, bespoke requirements of research and clinical trial projects globally.

Accredited laboratory service

Cost effective solution

Offers greater flexibility

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

EVidence Investigator

SARS-CoV-2 RBD & NP Array


COVID-19 Disease Management